The coverage cards

Ask who pays for this exact use.

Take the medicine name and the condition being treated to the plan. Ask for the answer in writing.

Questions for the plan

  1. Medicine Is this product listed?
  2. Purpose Is this use covered?
  3. Paperwork What has to be sent?
Keep the plan’s answer beside the written quote.

An insurance plan’s covered medicines appear in a list called its formulary.

Ordinary Medicare coverage and a temporary program differ.

The usual drug benefit

Medicare calls its prescription drug benefit Part D.

Ordinary Part D did not pay for medicines prescribed solely for weight loss as of September 26, 2026.

Part D could cover a medicine for another accepted medical use, subject to the plan’s rules.

An eligible use does not guarantee payment.

Ask the plan to consider the actual reason for the prescription.

The temporary weight-medicine program

The body uses a signal called GLP-1 to affect hunger and blood sugar; these medicines act like that signal.

Eligible Medicare GLP-1 Bridge members were offered a monthly copay of $50 as of September 26, 2026. A copay is their payment for the medicine.

The program ran separately from usual Part D payments, beginning July 1, 2026, and ending December 31, 2027.

Part D sets a yearly limit on what patients pay themselves for covered medicines; this is called the out-of-pocket cap.

The $50 program payment did not move you closer to that limit, so these payments were extra spending outside the cap.

Who qualified depended on age, weight, certain health problems, the kind of Medicare plan and earlier drug payments.

For type 2 diabetes, people had to ask their ordinary Part D plan about coverage instead of using this program.

Write down whether the price comes from ordinary insurance or the temporary program. Keep the rules for qualifying beside it.

Who could qualify for the $50 program?

The rules checked September 26, 2026, required age 18 or older and used weight and health conditions from when treatment began.

BMI, or body mass index, is a number comparing weight with height. Ask your care professional for your number.

A BMI of 35 or higher could satisfy the weight requirement without any of the additional diagnoses below.

At BMI 30 or higher, qualifying diagnoses were certain heart failure, blood pressure still high despite treatment, or kidney disease at stage 3a or more severe.

The heart-failure rule covered the type where a normal share of the blood inside the heart is pumped out.

The blood-pressure rule required a reading above 140 mm Hg on top or above 90 mm Hg on the bottom, even with two blood-pressure medicines.

Blood-pressure readings use mm Hg as their unit; ask your care professional to check your numbers.

At BMI 27 or higher, qualifying conditions included prediabetes: blood sugar above normal but below diabetes levels.

A previous heart attack or stroke, or disease causing symptoms in arteries carrying blood to the arms or legs, also qualified at that BMI.

Your Medicare plan had to be either a separate drug plan under Part D or a Medicare Advantage plan with drug coverage that coordinates care.

If your Part D plan had paid during 2026 for your GLP-1 medicine, the temporary program was unavailable to you in 2026.

These checks did not guarantee eligibility; other medical exclusions and approval paperwork also applied.

Ask your prescriber for your kidney-disease stage, the label for how far it has progressed, if that is the condition you need checked.

Ask your prescriber to check your diagnosis, weight record and past medicine payments against the full program rules. Ask the plan to confirm that your plan qualifies.

Questions for private insurance

Ask whether this product is covered for the condition being treated and how much of the bill you would pay.

When you request the plan’s agreement to coverage before a medicine is supplied, that step is called prior authorization.

Ask whether prior authorization is needed, who sends it and how to follow its progress.

If coverage is declined, ask for the reason and the plan’s review process in writing.